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Abstract
Background: To explore the diagnostic benefit of an additional image fusion of the sagittal plane in addition to the
standard axial image fusion, using a sensor-based MRI/US fusion platform.
Methods: During July 2013 and September 2015, 251 patients with at least one suspicious lesion on mpMRI (rated by
PI-RADS) were included into the analysis. All patients underwent MRI/US targeted biopsy (TB) in combination with a 10
core systematic prostate biopsy (SB). All biopsies were performed on a sensor-based fusion system. Group A included
162 men who received TB by an axial MRI/US image fusion. Group B comprised 89 men in whom the TB was performed
with an additional sagittal image fusion.
Results: The median age in group A was 67 years (IQR 61–72) and in group B 68 years (IQR 60–71). The median PSA
level in group A was 8.10 ng/ml (IQR 6.05–14) and in group B 8.59 ng/ml (IQR 5.65–12.32). In group A the proportion of
patients with a suspicious digital rectal examination (DRE) (14 vs. 29%, p = 0.007) and the proportion of primary biopsies
(33 vs 46%, p = 0.046) were significantly lower. The rate of PI-RADS 3 lesions were overrepresented in group A compared
to group B (19 vs. 9%; p = 0.044). Classified according to PI-RADS 3, 4 and 5, the detection rates of TB were 42, 48, 75% in
group A and 25, 74, 90% in group B. The rate of PCa with a Gleason score ≥7 missed by TB was 33% (18 cases) in group
A and 9% (5 cases) in group B; p-value 0.072. An explorative multivariate binary logistic regression analysis revealed that
PI-RADS, a suspicious DRE and performing an additional sagittal image fusion were significant predictors for PCa
detection in TB. 9 PCa were only detected by TB with sagittal fusion (sTB) and sTB identified 10 additional
clinically significant PCa (Gleason ≥7).
Conclusion: Performing an additional sagittal image fusion besides the standard axial fusion appears to improve the
accuracy of the sensor-based MRI/US fusion platform.
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Background
Prostate cancer (PCa) is the most common malignancy of
men and the only tumour, which is diagnosed according
to the guidelines by untargeted systematic biopsies of the
entire organ [1, 2]. Because prostate cancer is often not vi-
sualized in conventional transrectal ultrasound, there is a
risk to miss clinically significant PCa (Gleason ≥7) with a
random systematic transrectal prostate biopsy (SB) [3, 4].
Due to a high soft-tissue contrast, a high resolution (T2-
weighted anatomical sequences) and the registration of
functional parameters (diffusion-weighted and dynamic
contrast-enhanced sequences (DWI and DCE), MR spec-
troscopy imaging) a multiparametric magnetic resonance
imaging (mpMRI) of the prostate provides a high sensitiv-
ity, specificity and negative predictive value in the detec-
tion and localization of clinically significant prostate
cancers [5, 6]. For standardization of evaluation of the
mpMRI the “European Society of Urogenital Radiology”
(ESUR) established the “Prostate Imaging Reporting and
Data System” (PI-RADS), which introduced a 5-point
Likert scale for each region (peripheral and central glan-
dular sections) with corresponding scores for each se-
quence (T2, DWI, DCE, and MR-Spectroscopy) [7, 8].
The correlation of the level of PI-RADS with the overall
detection rate of PCa and the detection of significant PCa
has been demonstrated in various studies [9–13]. The in-
creasing utilization of mpMRI of the prostate and the con-
secutive MRI/ultrasound fusion guided targeted biopsy
(TB) resulted in an improved detection of PCa compared
to SB, the current standard of care [14–17]. A difficulty is
the exact fusion of mpMRI with transrectal ultrasound for
TB. Various possibilities of MRI/ultrasound (MRI/US)
image fusion, such as cognitive fusion, sensor-based fusion
or organ-based fusion are available to perform TB. Despite
the technological progress of different fusion platforms,
several studies have shown that clinically significant PCa
can still be overlooked by TB [17–20]. For the sensor-
bases TB we previously analyzed the possible pitfalls of
TB, such as reader variability for mpMRI, an imprecise
targeting of the suspicious lesion [21]. Traditionally
sensor-based fusion of the MRI image and the real-time
ultrasound image is performed by the operator in the axial
plane according to anatomical landmarks (i.e. prostatic
apex, periprostatic vessels, BPH nodes etc.). In order to
further improve the targeting accuracy and reduce a pos-
sible image fusion error, this study evaluated the use of an
additional image fusion in the sagittal plane according to a
3-point technique. In a cohort of 791 men, who under-
went a MRI/US fusion biopsy with an organ-based fusion
system, Hong et al. demonstrated that the combination of
axial and sagittal approaches detected more clinically
significant PCa [22]. For sensor-based fusion platforms




In the period of July 2013 to September 2015, 251 pa-
tients, who showed at least one suspicious lesion on
mpMRI (PI-RADS ≥3) and underwent a consecutive TB in
combination with a 10-core systematic prostate biopsy
(SB), were consecutively included into the retrospective
analysis. The indication for a mpMRI has largely been
provided by attending outpatient urologists. Parts of the
cohort were analysed in a previous study [13]. All patients
were recorded regardless to the number of prior prostate
biopsies. The data collection was based on the patients
medical history, clinical findings and the physical patient
files. Patient data was prospectively collected in a START
conform database [23]. The analysis in regard to the axial
and sagittal image fusion was performed retrospectively.
All patients signed an informed consent for the interven-
tion, data acquisition and data evaluation. The study was
performed according to the declaration of Helsinki and
the analysis was approved by the Institutional Review
Board of the Charité University Medicine Berlin.
Multiparametric magnetic resonance imaging
A 3-Tesla mpMRI (Magnetom Skyra, Siemens Medical Sys-
tems, Erlangen, Germany) without an endorectal coil was
performed for all patients before prostate biopsy. The MRI
protocol contained high spatial resolution T2-weighted
turbo spin-echo sequences in axial, sagittal and coronal
orientation, axial turbo spin-echo T1 weighted images, axial
diffusion weighted images (b-values 0.400 and 800 s/mm2)
and dynamic contrast-enhanced sequences. The evaluation
of the mpMRI was performed by experienced radiologists
according to the guidelines of the European Society of
Urogenital Radiology (ESUR) [8]. From a PI-RADS score of
3, the indication for MRI/US fusion biopsy was made.
MRI-ultrasound fusion prostate biopsy and systematic
biopsy
The prostate biopsies were performed under antibiotic
prophylaxis with a fluoroquinolone according to the EAU
guidelines [2], with a high-end ultrasound device HiVision
Preirus (Hitachi Medical Systems, Tokyo, Japan) and an
endocavity endfire probe (EUP V53W, Hitachi Medical
Systems, Tokyo, Japan). All biopsies were taken in lithot-
omy position. At first TB were performed. T2 and DWI
sequences of the axial planes in mpMRI were imported to
the ultrasonic device. After that, the suspicious lesions
were marked in axial orientation of the mpMRI sequences
by the urologist experienced with mpMRI. The MRI/US
image fusion was performed using sensor-based registra-
tion. The movement of the probe with an attached tracker
was detected in a low magnetic field (0.1 Tesla), which
was generated by a mini bird receiver. Until December
2014 only axial MRI/US image fusion was performed. For
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this purpose, the same plane in ultrasound and MRI was
identified according to anatomical landmarks (prostatic
apex, periprostatic vessels, BPH nodes, intraprostatic
cysts) Depending on the anatomical conditions, the angle
of axial plane in the MRI image was corrected to match
the angulation of the ultrasound probe and image. The
previously marked suspect lesions were transferred to the
real-time ultrasound image by the platform’s software,
followed by a 2–5 targeted biopies in an axial orientation.
After an analysis of possible reasons for targeted biopsy
failure, as of December 2014 the targeted biopsies were
performed after MRI/US image fusion in both the axial
and sagittal plane [21]. The total number of targeted biop-
sies remained unchanged. For the sagittal image fusion, a
T2-weighted sequence in sagittal orientation was used to
mark the bladder neck, the apex of the prostate and the
seminal vesicle angle. Based on these marks the MRI and
the ultrasound image were fused by the software. There-
after, TB was carried out in a sagittal orientation of the
MRI and ultrasound image. For sampling, we used a long
biopsy needle (18 g × 25 cm, Bard Magnum biopsy instru-
ment, Tempe, United States). After performing TB, local
anaesthesia with a bupivacaine was injected at the dorsal
prostatic capsule and a 10-core SB was conducted without
changing the examiner. The SB scheme included cores
from: left/right apex, left/right lateral mid gland, left/right
base, left/right ventral and left/right para-urethral. All
tissue-samples were documented by their extraction loca-
tion and shipped separately for histopathological evalu-
ation by our experienced pathologists.
Group distribution
Group A included all patients who have received an MRI/
US image fusion only in the axial plane. Group B, are
included all patients who have received MRI/US image
fusion in the axial and sagittal plane. Figure 1 shows a flow
chart for the patient inclusion and the group distribution.
Statistical analysis
PASW Version 22 (SPSS Inc. 1998–2010, Chicago, Illinois
60606, USA) was used for statistical analyses. Categorical
data were presented by absolute and relative frequencies.
Continuous variables were measured by means and stand-
ard deviation when normal distributed or by medians and
quartiles. Continuous variables were evaluated with the
Kolmogorov-Smirnov-test for normal distribution. We
used chi-square test, Student’s t-test and Mann-Whitney U
test to calculate statistical differences between numerical
and categorical variables. Univariate and multivariate
binary regression analysis were performed to evaluate sig-
nificant parameters in the descriptive analysis as predictors
for PCa detection. A p-value of p <0.05 was considered
statistical significant.
Results
Demographic data, clinical characteristics and MRI
findings are presented in Table 1 divided in group A
(patients without additional sagittal image fusion) and
group B (patients with additional sagittal image fusion).
The median age in group A was 67 years (IQR 61–72)
and in group B 68 years (IQR 60–71). Both groups
showed statistically similar prostate volumes (48 vs.
50 ml). The median PSA level in group A was 8.10 ng/
ml (IQR 6.05–14.00) and in group B 8.59 ng/ml (IQR
5.65–12.32). The proportion of patients with a suspi-
cious digital rectal examination (DRE) (14 vs. 29%, p =
0.007) and the proportion of patients with primary
biopsies (33 vs 46%, p = 0.041) were significantly lower
in group A. The rate of PI-RADS 3 lesions were over-
represented in group A (19 vs. 9%; p = 0.044). With 43%
compared to 30% in group A PI-RADS 5 lesions were
more frequently represented in group B (p = 0.051). No
significant differences were observed for lesion posi-
tions, number of suspicious lesions in mpMRI and le-
sion sizes. The mean number of cores taken per patient
and the mean number of TB per patient were signifi-
cant higher in Group A (13.7 vs. 13.2 and 3.8 vs. 3.4;
p = 0.009 and 0.031). The analysis showed a significant
higher overall cancer detection rate (CDR) (85 vs. 72%;
p = 0.019) and a significant higher detection rate in TB
(76 vs. 55%; p = 0.001) in group B, please see Table 2.
Furthermore there was a significant lower number of
patients diagnosed with a clinically significant PCa in
group A (61 vs. 78%; p = 0.025). Classified according to
Fig. 1 Patient inclusion and group distribution. Group A included patients between July 2013 and December 2014 where an axial targeted biopsy was
the standard Group B included patients between December 2014 and September 2015 where and axial and sagittal targeted biopsy was performed
without increasing the total number of targeted biopsy cores
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PI-RADS 3, 4 and 5, the detection rates of TB were 42,
48, 75% in group A and 25, 74, 90% in group B. The rate
of PCa with a Gleason score ≥7 missed by TB was 33%
(18 cases) in group A and 9% (5 cases) in group B (p =
0.072). The overall cancer detection rates and the PI-
RADS based analyses for SB and TB for men without
suspicious DRE and prior negative biopsy are shown in
Additional file 1 Table S1 and Additional file 2 Table S2.
An explorative multivariate binary logistic regression
analysis revealed that PI-RADS, a suspicious DRE and
performing an additional sagittal image fusion were sig-
nificant predictors for PCa detection in TB, please see
Table 3. Table 4 shows the comparison of the biopsy
results of the axial (aTB) and sagittal (sTB) MRI/US
fusion biopsy. Depending on PI-RADS, lesion diameter
and lesion localization, PCa detection rates of aTB and
sTB were statistically equivalent except a higher detection
of PCa by aTB for PI-RADS 4 lesions (70 vs. 44%, p =
0.007). Furthermore, Table 4 shows the additional detec-
tion of PCa in total and of PCa with a Gleason score ≥7
due sTB depending on PI-RADS, lesion diameter and
lesion localization. Overall, nine PCas were only detected
by sTB and sTB identified 10 additional clinically signifi-
cant PCa (Gleason ≥7).
Discussion
Since the introduction of MRI/US fusion biopsy of the
prostate, several studies have demonstrated an improve-
ment in prostate cancer detection rates as well as the iden-
tification of clinically relevant tumours [14, 15, 24–26]. Due
to this increasing value of MRI/US fusion biopsy for






Overall CDR 117 (72%) 76 (85%) 0.019
SB 108 (67%) 68 (76%) 0.115
TB 89 (55%) 68 (76%) 0.001
PI-RADS 3 (n = 39)
Overall CDR 17 (55%) 5 (63%) >0.999
SB 15 (48%) 3 (38%) 0.702
TB 13 (42%) 2 (25%) 0.450
PI-RADS 4 (n = 126)
Overall CDR 55 (66%) 36 (84%) 0.058
SB 48 (58%) 33 (77%) 0.049
TB 40 (48%) 32 (74%) 0.007
PI-RADS 5 (n = 86)
Overall CDR 45 (94%) 35 (92%) >0.999
SB 45 (94%) 32 (84%) 0.175
TB 36 (75%) 34 (90%) 0.102
Detected GS ≥7 in TB 54 (61%) 53 (78%) 0.025
Missed PCa (GS≥7) in TB 18 (33%*) 5 (9%*) 0.072
CDR = Cancer Dection Rate; GS = Gleason Score; SB = Random Biopsy; TB = Target
biopsy; * % of GS ≥7 detected by TB
Table 3 Predictors for prostate cancer detection in the Targeted
Biopsy
Univariate analysis Multivariate analysis
OR p-value OR p-value
Suspicious DRE 4.539 <0.001 2.777 0.024
Primary biopsy 1.175 0.553
PI-RADS 2.712 <0.001 2.240 <0.001
Sagittal image fusion 2.656 0.001 2.105 0.017
Table 1 Patient demographics and magnetic resonance






Median (IQR) age, years 67 (61–72) 68 (60–71) 0.846
Median (IQR) PSA. ng/ml 8.10 (6.05–14.00) 8.59 (5.65–12.32) 0.997
Median IQR) f/t PSA-ratio,% 12 (9–17) 13 (9–19) 0.309
Median (IQR) prostate
volume, ml
48 (35–60) 50 (37–70) 0.087
Suspicous DRE, n (%) 23 (14%) 26 (29%) 0.007
No. of prior biopsies, n (%)
Primary biopsy 53 (33%) 41 (46%) 0.041
1 59 (36%) 28 (32%) 0.489
2 33 (20%) 13 (15%) 0.308
≥3 17 (10%) 7 (8%) 0.655
Localization of lesions with
maximum PI-RADS on mpMRI,
n (%)
Apex 72 (44%) 35 (39%) 0.505
Midgland 43 (27%) 32 (36%) 0.149
Base 47 (29%) 22 (25%) 0.555
Anterior 45 (28%) 28 (32%) 0.563
Median (IQR) no. of lesions
per patient
1 (1–2) 1 (1–2) 0.451
Maximum diameter of
lesions (mm)
14 (10–17) 13 (10–18) 0.885
Mean (SD) of cores taken
per patient
13.7 (±1.6) 13.2 (±1.2) 0.009
Mean (SD) TBs per patient 3.8 (±1.5) 3.4 (±0.9) 0.031
Maximum mpMRI Score,
n (%)a
PI-RADS 3 31 (19%) 8 (9%) 0.044
PI-RADS 4 83 (51%) 43 (48%) 0.693
PI-RADS 5 48 (30%) 38 (43%) 0.051
PSA prostate-specific antigen, IQR interquartile range, SD standard deviation,
DRE digital rectal examination, mpMRI multiparametric magnetic resonance
imaging, PI-RADS Prostate Imaging Reporting and Data System, TB
targeted biopsy
aFor patients with multiple lesions the highest PI-RADS score is stated
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primary diagnosis and monitoring of prostate cancer vari-
ous fusion systems have been established. A variety fusion
systems (UroNav, BiopSee, Urostation, Artemis, HiVison-
Preirus, etc.) have been reported in the current literature
[13, 14, 22, 24, 26, 27]. Uniform treatment regimens for the
implementation of MRI/US fusion biopsies do not exist. In
a large patient cohort Hong et al. demonstrated for organ
based MRI/US fusion biopsies that the combination of sa-
gittal and axial biopsy approaches identified additional clin-
ically significant prostate cancers [22]. It can be assumed
that the correctness of the image fusion of MRI and trans-
rectal ultrasound has an important influence on the accur-
acy of targeted sampling. Our study showed a significant
increase in prostate cancer detection rate of TB by 55% in
the group without sagittal fusion to 76% in the group with
additional sagittal fusion and the improvement remained
even when men with a positive DRE and a primary biopsy
were excluded. In addition, the proportion of detected clin-
ically significant PCa (Gleason-score ≥7) increased from
61% in group A to 78% in group B. The sole analysis of the
detection rates of axial TB results in an increase of 56 to
66% in group B. The observed increase in detection rates
might be related to various factors. In the sensor-based
MRI/US image fusion, the same layers in the T2-weighted
MRI sequence and the transrectal ultrasound image in axial
or sagittal orientation are fused. Identifying the same layers
in MRI and US are the basis of fusion accuracy. Angular
deviations of the display plane in transrectal ultrasound and
MRI lead to inaccuracies of image fusion. In our study, the
angle correction for axial image fusion was carried out
manually by the urologist. In the sagittal image fusion, the
angular offset is software-based by three identical points,
which are simultaneously marked in MRI and ultrasound
in two different layers. Gaziev et al. showed an increase in
the detection rate of prostate cancer by performing perineal
MRI/US fusion biopsies of the prostate with increasing ex-
perience of the examiner [28]. It is tempting to speculate,
that in our study the learning curve of the examiner has
likewise lead to an increase in the detection rate in the TB
after implementation of additional sagittal image fusion.
Another important factor influencing the detection rate of
TB is the PI-RADS score [12, 13]. Our study cohort showed
a significant decrease of percentage of PI-RADS 3 lesions
and a non-significant increase in the proportion of PI-
RADS 5 lesions in the patient group with additional sagittal
fusion. Also in the univariate and multivariate regression
analysis the level of PI-RADS was identified as a significant
predictor for PCa detection. This may have occurred to an
increased PCa detection in group B, but the sagittal image
fusion remained an independent predictor for cancer detec-
tion by TB. A suspicious digital rectal examination as de-
scribed by Radtke et al. and Potter et al. presents a further
risk factor for the detection of PCa in TB and SB [18, 29].
Similar to the previously published studies, our univariate
and multivariate regression analyses of the whole cohort
revealed a significant correlation of a suspicious DRE with
PCa detection rate. The higher TB detection rate in group
B, that included more men with a suspicious DRE, may
therefore have been influenced, but the higher detection
rate in group B compared to group A persisted when the
analysis excluded men with a suspicious DRE. In our
regression analysis, the proportion of biopsy naive men was
not a significant predictor for PCa detection, although two
large studies showed an influence on cancer detection
Table 4 Cancer Detection Rate of the Targeted Biopsy in relation to an axial and sagittal image fusion




Overall 68 (76%) 59 (66%) 50 (56%) 9 (13%) 10 (19%)
PI-RADS
3 (n = 8) 2 (25%) 2 (25%) 2 (25%) 0 0
4 (n = 43) 32 (74%) 30 (70%) 19 (44%) 2 (5%) 4 (9%)
5 (n = 38) 34 (90%) 27 (71%) 29 (76%) 7 (18%) 6 (16%)
Maximum diameter of lesion
1–10 (n = 27) 18 (67%) 15 (56%) 10 (37%) 3 (11%) 3 (11%)
11–20 (n = 50) 38 (76%) 33 (66%) 29 (58%) 5 (10%) 5 (10%)
>20 (n = 12) 12 (100%) 11 (92%) 11 (92%) 1 (8%) 2 (17%)
Localization of lesion
Apex (n = 35) 26 (74%) 23 (66%) 19 (54%) 3 (9%) 3 (9%)
Midgland (n = 32) 23 (72%) 18 (56%) 15 (47%) 5 (16%) 5 (16%)
Base (n = 22) 19 (86%) 18 (82%) 16 (73%) 1 (5%) 2 (9%)
Anterior (n = 28) 26 (93%) 22 (79%) 22 (79%) 4 (14%) 5 (18%)
aTB = axial fusion TB; sTB = sagittal fusion TB; * compared to overall CDR or TB (aTB + sTB);
#Either detection of GS ≥7 only by sTB or Gleason upgrade in the sTB biopsy core compared to the aTB core; percentage of GS≥7 detected by TB (aTB + sTB) n = 53
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[12, 22]. Therefore, the significantly higher proportion of
primary biopsies in group B may have affected the detec-
tion rate of the TB. Again, the improved detection rate in
group B remained when men with a positive DRE and a
primary biopsy were excluded from the analysis.
The additional implementation of the sagittal image
fusion resulted in an increase in the detection rate of 10%
for TB. By sagittal fusion, nine (13%) additional prostate
cancers were detected and ten (19%) additional clinically
significant tumors were identified. The improvement of the
axial TB, when adding a sagittal TB was independent of the
lesion size or localization of the lesions. Moreover, perform-
ing a sagittal image fusion was a significant predictor in
univariate and multivariate regression analysis for the
detection of prostate cancer in the TB. In the group of
patients with sagittal fusion, the proportion of overlooked
clinically significant tumors by TB dropped to 9% com-
pared to 33% in the group of patients without sagittal
fusion. The reduced rate of missed PCa after the introduc-
tion of the sagittal image fusion was not accompanied with
an increase of the number of targeted biopsies.
Adding the sagittal image fusion when performing TB on
a sensor-based platform may reduce the targeting error that
may be inevitable in some cases [21]. In our institution we
have therefore established the additional sagittal image
fusion firmly in our MRI/US fusion biopsy protocol.
Because of the retrospective study design the investiga-
tion has several limitations. Unconsidered confounders
may have also influenced the study results, e.g. a selection
bias of patients by referring outpatient urologist. The in-
homogeneity of the two study groups in terms of baseline
characteristics may have affected the study results. To en-
sure the data consistency, we performed logistic regression
analyses for the evaluation of predictors of PCa detection
by targeted biopsy. In order to clearly demonstrate the im-
pact of an additional sagittal image fusion on the detection
rate of TB would require prospective randomized studies.
Conclusion
Performing a sagittal image fusion in addition to the
standard the axial fusion improves the accuracy to detect
PCa by targeted biopsies performed with a sensor-based
MRI/US fusion platform.
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Abbreviations
DCE: Dynamic contrast-enhanced sequences; DWI: Diffusion-weighted;
ESUR: European society of urogenital radiology; mpMRI: Multiparametric
magnetic resonance imaging; MRI/US: MRI/ultrasound; PCa: Prostate cancer;






Availability of data and materials
The datasets during and/or analysed during the current study available from
the corresponding author on reasonable request.
Authors’ contributions
KG, HC, CK: Protocol/project development. KG, HC, JB, MK, PA, MH: Data
collection or management. KG, HC, CK: Data analysis. KG, HC, CK: Manuscript
writing/editing. PA, JN, SH, KM: Critical manuscript revision. JN, SH, KM, CK:
Supervision.
Competing interests
H. Cash reports receiving honoraria as a speaker on national conferences for
Hitachi Medical Systems. All other authors have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
All patients signed an informed consent for the intervention, data acquisition
and data evaluation. The study was performed according to the declaration
of Helsinki. The analysis was approved by the Institutional Review Board of
the Charité University Medicine Berlin.
Author details
1Department of Urology, Charité — University Medicine Berlin,
Hindenburgdamm 30, 12203 Berlin, Germany. 2Departement of Radiology,
Charité — University Medicine Berlin, Hindenburgdamm 30, 12203 Berlin,
Germany.
Received: 8 July 2016 Accepted: 23 December 2016
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;
65(1):5–29.
2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al.
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local
treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124–37.
3. Rodriguez-Covarrubias F, Gonzalez-Ramirez A, Aguilar-Davidov B, Castillejos-
Molina R, Sotomayor M, Feria-Bernal G. Extended sampling at first biopsy
improves cancer detection rate: results of a prospective, randomized trial
comparing 12 versus 18-core prostate biopsy. J Urol. 2011;185(6):2132–6.
4. Campos-Fernandes JL, Bastien L, Nicolaiew N, Robert G, Terry S, Vacherot F,
et al. Prostate cancer detection rate in patients with repeated extended
21-sample needle biopsy. Eur Urol. 2009;55(3):600–6.
5. Futterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, et al.
Can clinically significant prostate cancer Be detected with multiparametric
magnetic resonance imaging? a systematic review of the literature. Eur Urol.
2015;68(6):1045–53.
6. Arumainayagam N, Ahmed HU, Moore CM, Freeman A, Allen C, Sohaib SA,
et al. Multiparametric MR imaging for detection of clinically significant
prostate cancer: a validation cohort study with transperineal template
prostate mapping as the reference standard. Radiology. 2013;268(3):761–9.
7. Hamoen EH, de Rooij M, Witjes JA, Barentsz JO, Rovers MM. Use of the
prostate imaging reporting and data system (PI-RADS) for prostate cancer
detection with multiparametric magnetic resonance imaging: a diagnostic
meta-analysis. Eur Urol. 2015;67(6):1112–21.
8. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al.
ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22(4):746–57.
9. Arsov C, Rabenalt R, Blondin D, Quentin M, Hiester A, Godehardt E, et al.
Prospective randomized trial comparing magnetic resonance imaging
Günzel et al. BMC Urology  (2017) 17:7 Page 6 of 7
(MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal
ultrasound-guided prostate biopsy in patients with prior negative biopsies.
Eur Urol. 2015;68(4):713–20.
10. Baco E, Rud E, Eri LM, Moen G, Vlatkovic L, Svindland A, et al. A
Randomized Controlled Trial To Assess and Compare the Outcomes of
Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and
Transrectal Ultrasound Images and Traditional 12-core Systematic
Biopsy. Eur Urol. 2016;69(1):149–56.
11. Borkowetz A, Platzek I, Toma M, Laniado M, Baretton G, Froehner M, et al.
Comparison of systematic transrectal biopsy to transperineal magnetic
resonance imaging/ultrasound-fusion biopsy for the diagnosis of prostate
cancer. BJU Int. 2015;116(6):873–9.
12. Filson CP, Natarajan S, Margolis DJ, Huang J, Lieu P, Dorey FJ, et al. Prostate
cancer detection with magnetic resonance-ultrasound fusion biopsy: The
role of systematic and targeted biopsies. Cancer. 2016;122(6):884–92.
13. Cash H, Maxeiner A, Stephan C, Fischer T, Durmus T, Holzmann J, et al.
The detection of significant prostate cancer is correlated with the Prostate
Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound
fusion biopsy. World J Urol. 2016;34(4):525–32.
14. Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al.
Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided
biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390–7.
15. Siddiqui MM, Rais-Bahrami S, Truong H, Stamatakis L, Vourganti S, Nix J,
et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly
upgrades prostate cancer versus systematic 12-core transrectal ultrasound
biopsy. Eur Urol. 2013;64(5):713–9.
16. Pokorny MR, de Rooij M, Duncan E, Schroder FH, Parkinson R, Barentsz JO, et al.
Prospective study of diagnostic accuracy comparing prostate cancer detection
by transrectal ultrasound-guided biopsy versus magnetic resonance (MR)
imaging with subsequent MR-guided biopsy in men without previous prostate
biopsies. Eur Urol. 2014;66(1):22–9.
17. Salami SS, Ben-Levi E, Yaskiv O, Ryniker L, Turkbey B, Kavoussi LR, et al. In
patients with a previous negative prostate biopsy and a suspicious lesion on
magnetic resonance imaging, is a 12-core biopsy still necessary in addition to
a targeted biopsy? BJU Int. 2015;115(4):562–70.
18. Radtke JP, Kuru TH, Boxler S, Alt CD, Popeneciu IV, Huettenbrink C, et al.
Comparative analysis of transperineal template saturation prostate biopsy
versus magnetic resonance imaging targeted biopsy with magnetic
resonance imaging-ultrasound fusion guidance. J Urol. 2015;193(1):87–94.
19. Distler F, Radtke JP, Kesch C, Roethke M, Schlemmer HP, Roth W, et al.
[Value of MRI/ultrasound fusion in primary biopsy for the diagnosis of
prostate cancer]. Urologe A. 2016;55(2):146–55.
20. Radtke JP, Schwab C, Wolf MB, Freitag MT, Alt CD, Kesch C, et al.
Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal
Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with
Radical Prostatectomy Specimen. Eur Urol. 2016;70(5):846–853.
21. Cash H, Gunzel K, Maxeiner A, Stephan C, Fischer T, Durmus T, et al. Prostate
cancer detection on transrectal ultrasonography-guided random biopsy
despite negative real-time magnetic resonance imaging/ultrasonography
fusion-guided targeted biopsy: reasons for targeted biopsy failure. BJU Int.
2016;118(1):35–43.
22. Hong CW, Rais-Bahrami S, Walton-Diaz A, Shakir N, Su D, George AK, et al.
Comparison of magnetic resonance imaging and ultrasound (MRI-US) fusion-
guided prostate biopsies obtained from axial and sagittal approaches. BJU Int.
2015;115(5):772–9.
23. Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Futterer JJ, Gill IS, et
al. Standards of reporting for MRI-targeted biopsy studies (START) of the
prostate: recommendations from an international working group. Eur Urol.
2013;64(4):544–52.
24. Sonn GA, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, et al. Value
of targeted prostate biopsy using magnetic resonance-ultrasound fusion in
men with prior negative biopsy and elevated prostate-specific antigen. Eur
Urol. 2014;65(4):809–15.
25. Wysock JS, Rosenkrantz AB, Huang WC, Stifelman MD, Lepor H, Deng FM,
et al. A prospective, blinded comparison of magnetic resonance (MR)
imaging-ultrasound fusion and visual estimation in the performance of
MR-targeted prostate biopsy: the PROFUS trial. Eur Urol. 2014;66(2):343–51.
26. Delongchamps NB, Peyromaure M, Schull A, Beuvon F, Bouazza N, Flam T,
et al. Prebiopsy magnetic resonance imaging and prostate cancer
detection: comparison of random and targeted biopsies. J Urol.
2013;189(2):493–9.
27. Kuru TH, Roethke MC, Seidenader J, Simpfendorfer T, Boxler S, Alammar K, et al.
Critical evaluation of magnetic resonance imaging targeted, transrectal
ultrasound guided transperineal fusion biopsy for detection of prostate cancer.
J Urol. 2013;190(4):1380–6.
28. Gaziev G, Wadhwa K, Barrett T, Koo BC, Gallagher FA, Serrao E, et al. Defining
the learning curve for multiparametric magnetic resonance imaging (MRI) of
the prostate using MRI-transrectal ultrasonography (TRUS) fusion-guided
transperineal prostate biopsies as a validation tool. BJU Int. 2016;117(1):80–6.
29. Potter SR, Horniger W, Tinzl M, Bartsch G, Partin AW. Age, prostate-specific
antigen, and digital rectal examination as determinants of the probability of
having prostate cancer. Urology. 2001;57(6):1100–4.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Günzel et al. BMC Urology  (2017) 17:7 Page 7 of 7
